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A B S T R A C T   
Focal segmental glomerulosclerosis (FSGS) is a major cause of familial nephrotic syndrome. We generated 20 induced pluripotent stem cell lines from patients 
diagnosed with FSGS. The iPSC lines include 8 female and 12 male lines and cover a donor age range from 31 to 78. The lines were generated from peripheral blood 
mononuclear cells by integration-free reprogramming using Sendai virus vectors. Cell lines were fully characterized regarding their pluripotency and differentiation 
potential, and quality controlled for karyotypic integrity, identity and clearance of reprogramming vectors. The generated cell lines represent a valuable tool for 
disease modelling and drug development for FSGS.   
1. Resource table  
Unique stem cell lines 
identifier 
BIHi006-D, BIHi007-A, BIHi008-A, BIHi009-A, 
BIHi010-A, BIHi011-A, BIHi012-A, BIHi015-A, 
BIHi016-A, BIHi017-A, BIHi018-A, BIHi019-A, 
BIHi024-A, BIHi025-A, BIHi028-B, BIHi029-A, BIHi030- 
C, BIHi031-B, BIHi032-A, BIHi038-B 
Alternative names of 
stem cell lines 
N/A 
Institution Charité – Universitätsmedizin Berlin, Berlin Institute of 
Health (BIH) Berlin, Germany 
Contact information of 
distributor 
BIH Stem Cell Core FacilityHarald Stachelscheid, 
Sebastian Diecke (stemcellcore@bihealth.de) 
Type of cell lines hiPSC 
Origin human 




sendai virus (Oct3/4, Sox2, c-Myc, Klf4) 
Multiline rationale same disease non-isogenic cell lines 
Gene modification no 
Type of modification N/A 
Associated disease Focal Segmental Glomerulosclerosis (FSGS) 
(continued on next column)  
(continued ) 
Gene/locus N/A 
Method of modification N/A 






Date archived/stock date 2017 
Cell line repository/bank Berlin Institute of Health, Stem Cell Core Facility https:// 
www.bihealth.org/en/research/core-facilities/stem-cells/ 
European Bank for induced pluripotent Stem Cells 
(EBiSC)  
https://cells.ebisc.org/ 
Ethical approval approved by the Ethics Committee of Charité – 
Universitätsmedizin Berlin (EA2/047/14)  
2. Resource utility 
FSGS is a severe chronic disease leading to renal failure. It is a cause 
of one sixth of all cases of nephrotic syndrome in children and adoles-
cents, and a leading cause of kidney failure in adults. The term FSGS 
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refers to a disease of primary podocyte injury, or a lesion caused by 
secondary scarring processes in any type of chronic kidney disease 
(Fogo, 2015). FSGS is characterized by glomerular injury, associated 
with podocyte damage and proteinuria. Causes include monogenetic 
mutations causing alterations in structural genes of the podocyte, many 
of which result in early onset of disease. These genes include nephrin 
(NPHS1), podocin (NPHS2), alpha-actinin-4 (ACTN-4), CD2-associated 
protein (CD2AP), Wilm’s tumor gene (WT1), and transient receptor 
potential cation 6 (TRPC6) (Woroniecki and Kopp, 2007). The recur-
rence of FSGS in many patients that received a healthy kidney graft 
points also to systemic factors in disease pathogenesis. Primary FSGS 
leads to end-stage renal disease (ESRD) with the current only available 
treatment options dialysis and kidney transplantation. Research to 
elucidate the diverse disease mechanism is urgently needed to enable 
the identification of new therapeutic targets and treatment strategies. 
We generated iPSC lines from 20 FSGS patients to build up a cohort to be 
utilized in research projects. 
3. Resource details 
PBMCs from 20 FSGS patients (8 female, 12 male, ages between 31 
and 78) (Table 1) were reprogrammed with the Sendai virus reprog-
ramming kit Cytotune 2.0 which includes vectors for the genes Oct3/4, 
Sox2, c-Myc and Klf4. For each iPSC line a single colony was picked after 
reprogramming, checked for the absence of Sendai viral vectors by PCR 
(data not shown) and expanded into a master cell bank. The master cell 
banks were subsequently characterized and quality controlled. All cell 
lines show the typical morphology of undifferentiated iPSC when 
maintained in E8 medium (Fig. 1A and Table 2). Immunofluorescence 
staining of adherent cells confirmed expression of the markers for un-
differentiated iPSCs octamer-binding transcription factor 3/4 (Oct3/4), 
Nanog, tumour rejection antigen (Tra-1–60) and stage specific embry-
onic antigen 4 (SSEA4) (Fig. 1B, Table 2). The quantification of these 
markers by flow cytometry confirmed their undifferentiated state. Tra- 
1–60 is expressed by more than 82%, Oct3/4 is expressed by more than 
97%, Nanog by more than 94% and SSEA4 by more than 95% of all cells 
in all cell lines. Unstained cells (grey histograms) served as negative 
gating control (Fig. 1C, Table 2, Suppl.Table 1). Furthermore, the Plu-
riTest analysis was applied to additionally confirm the stem cell identity. 
All cell lines reached high pluripotency and low novelty scores, com-
parable to a fully characterized iPSC line, which validates their iPSC 
identity (Fig. 1E, Table 2, Suppl.Table 2). The differentiation into all 
three germ-layers was tested for all iPSC lines and confirmed their 
pluripotent differentiation potential. To this end, the cells were tested 
either by teratoma formation in immunodeficient mice or by directed 
differentiation in vitro. All cell lines differentiated into endodermal, 
mesodermal and ectodermal cells, as shown by histological analysis of 
the teratomas or by quantification using flow cytometric analysis of the 
in vitro differentiated cells. Here, at least 68% co-expressed the ecto-
dermal markers Sox2+/Pax6+, 65% stained positive for the meso-
dermal markers CD140b+ or CD144+ and over 49% co-expressed the 
endodermal markers CD184+/Sox17+ in the ectodermal, mesodermal 
and endodermal differentiation assays, respectively. Unstained cells 
(grey) served as negative and gating control (Fig. 1D, Table 2, Suppl. 
Fig. 3, Suppl.Table 4). The karyotypes of the cell lines were tested by 
KaryoLite™ BoBs™ and by SNP analysis. The tests confirmed normal 
karyotypes for all cell lines but BIHi019-A. In BIHi019-A a deletion on 
the p-arm and a amplification on the q-arm of chromosome 20 were 
identified by both test methods (Fig. 1F, Fig. 1G, Table 2, Suppl.Table 3, 
Suppl.Fig. 2). The identity of all cell lines was confirmed by short tan-
dem repeat (STR) analysis of 10 genomic loci. Identical DNA profiles 
between patient’s PBMCs and the generated hiPSC line were observed 
(data available with journal). Moreover, tests for mycoplasma contam-
ination and donor screenings for HIV 1 + 2 Hepatitis B and Hepatitis C 
were all negative (Table 2, Suppl.Table 6). 
In summary, we generated integration free hiPSC lines from PBMCs 
of 20 FSGS patients which can be used to investigate the different dis-
ease mechanisms of FSGS and to identify possible drugs and therapies 
for FSGS. 
4. Materials and methods 
A detailed description of the methods for PBMCs isolation and 
erythroblast expansion, reprogramming, test for absence of the reprog-
ramming vector, culture of hiPSC, immunofluorescence staining for 
pluripotency markers, FACS staining and analysis for pluripotency and 
differentiation markers, PluriTest, in vitro directed differentiation into 
the three germ layers, karyotyping with KaryoLite™ BoBs™ and short 
tandem repeat analysis can be found in our earlier publication of the cell 
line BIHi002-A by Hennig et al. (2019). Information on antibodies and 
primers used can be found in Table 3. 
5. SNP analysis for karyotyping 
PBMCs and iPSCs where karyotyped using the Illumina platform and 
the OMNI-EXPRESS-8v1.4 Chip. The analysis was done in Karyostudio 
1.4. 
6. Teratoma formation 
The hiPSC were harvested as single cells using accutase treatment. A 
cell pellet of 1x106 was resuspended in 50 µl PBS w/o CaMg and 50 µl of 
Matrigel was added. The yielded 100 µl hiPSC suspensions were trans-
planted s.c. into the left flank of immunodeficient mouse. After about six 
to eight weeks when the tumour reached a size of more than 1 cm3 the 
animals were sacrificed, and the tumour was histologically evaluated. 
7. Mycoplasma screening 
The cell cultures and master banks were tested for Mycoplasma 
contaminations by the MycoAlertTM Mycoplasma Detection Kit accord-
ing to the manufacturer’s instructions. 
8. Screening for HIV 1 þ 2 Hepatitis B and Hepatitis C 
Testing of the donor PBMCs for viruses was conducted by external 
diagnostic laboratories (Central lab of Charite – Universitätsmedizin 
Berlin or IDEXX BioResearch, Ludwigsburg, Germany). 
Table 1 
Summary of lines.  
iPSC line names Gender Age Ethnicity Genotype of locus Disease 
BIHi012-A female 31 N/A N/A FSGS 
BIHi024-A female 31 N/A N/A FSGS 
BIHi031-B female 37 N/A N/A FSGS 
BIHi011-A female 44 N/A N/A FSGS 
BIHi016-A female 47 N/A N/A FSGS 
BIHi038-B female 51 N/A N/A FSGS 
BIHi008-A female 61 N/A N/A FSGS 
BIHi028-B female 78 N/A N/A FSGS 
BIHi029-A male 33 N/A N/A FSGS 
BIHi006-D male 36 N/A N/A FSGS 
BIHi018-A male 36 N/A N/A FSGS 
BIHi017-A male 37 N/A N/A FSGS 
BIHi015-A male 44 N/A N/A FSGS 
BIHi032-A male 45 N/A N/A FSGS 
BIHi010-A male 46 N/A N/A FSGS 
BIHi019-A male 49 N/A N/A FSGS 
BIHi007-A male 54 N/A N/A FSGS 
BIHi030-C male 61 N/A N/A FSGS 
BIHi025-A male 63 N/A N/A FSGS 
BIHi009-A male 67 N/A N/A FSGS  
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Fig. 1. Morphology, pluripotency, differentiation and karyotype of BIHi016-A, exemplary for all 20 iPSC lines. Data for the other lines can be found in the sup-
plementary materials. 
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Table 2 
Characterization and validation.  
Classification Test Result Data 
Morphology Phase contrast microscopy Normal PSC morphology Fig. 1A 
Suppl.Fig. 1 
Phenotype Qualitative analysis (immunocytochemistry) Positive stainings for Oct3/4, Nanog, Tra 1–60, SSEA-4 confirm the 
undifferentiated state of the iPSC lines 
Fig. 1B 
Suppl.Fig. 1 
Quantitative analysis (flow cytometry) High percentages of positively stained cells for Oct3/4, Nanog, Tra 1–60, 
SSEA-4 confirm the undifferentiated state of the iPSC lines 
Fig. 1C 
Suppl.Table 1 
PluriTest Pluripotency and novelty scores confirm the iPSC identity Fig. 1E 
Suppl.Table 2 
Genotype Karyotype (KaryoLite™ BoBs™) Normal karyotype in all lines, except for BIHi019-A 
Resolution: 4 probes per chromosome 
Fig. 1F 
Suppl.Table 3 
Karyotype (SNP array) Normal karyotype in all lines, except for BIHi019-A 
Resolution: ≈960000 markers 
Fig. 1G 
Suppl.Fig. 2 
Identity STR analysis 10 STR sites analysed, all matching between donor PBMCs and hiPSC 
lines 




Mycoplasma testing (luminescence) Negative Suppl.Table 6 
Clearance of 
reprogramming vectors 
PCR for SeV, SeV-cMyc, SeV-Klf4, SeV-KOS No detectable Sendai virus genes, vectors and transgenes Suppl.Table 5 
Differentiation potential Directed differentiation and quantitative 
analysis (flow cytometry) 






Teratoma formation and qualitative analysis 
(histology) 
Teratomas containing derivatives of all three germ layers were formed Suppl.Fig. 3 
Suppl.Table 4 
Donor screening HIV 1 + 2 Hepatitis B, Hepatitis C Negative Not shown but available 
with the author  
Table 3 
Reagents details.  
Antibodies used for immunocytochemistry/flow cytometry  
Antibody Dilution Company Cat # and RRID 
Pluripotency Markers Immunocytochemistry Anti-Nanog-PE 1:50 Cell Signaling Cat# 14955, RRID: N/A  
Anti-Oct3/4-APC 1:10 Miltenyi Biotec Cat# 130–105-607, RRID:AB_2653086  
Anti-SSEA4-PerCP-Vio700 1:10 Miltenyi Biotec Cat# 130–105-083, RRID:AB_2653526  
Anti-Tra1-60-Vio488 1:100 Miltenyi Biotec Cat# 130–106-872, RRID:AB_2654228 
Pluripotency Markers Flow Cytometry Anti-Nanog-PE 1:100 Cell Signaling Cat# 14955, RRID: N/A  
Anti-Oct3/4-APC 1:20 Miltenyi Biotec Cat# 130–105-555, RRID:AB_2653087  
Anti-Tra1-60-Vio488 1:700 Miltenyi Biotec Cat# 130–106-872, RRID:AB_2654228 
Differentiation Markers Flow Cytometry CD140b-APC 1:11 Miltenyi Biotec Cat# 130–105-280, RRID:AB_2655085  
CD144 (VE-Cadherin)-FITC 1:11 Miltenyi Biotec Cat# 130–100-742, RRID:AB_2655151  
CD184 (CXCR4)-APC 1:11 Miltenyi Biotec Cat# 130–109-844, RRID:AB_2655771  
Anti-PAX-6-APC 1:11 Miltenyi Biotec Cat# 130–107-776, RRID:AB_2653169  
Anti-Sox17-Vio515 1:50 Miltenyi Biotec Cat# 130–111-031, RRID:AB_2653497  
Anti-Sox2-PE 1:11 Miltenyi Biotec Cat# 130–104-994, RRID:AB_2653501  
Primers  
Target Forward/Reverse primer (5′-3′) 
Sendai virus vectors (PCR) SeV GGATCACTAGGTGATATCGAGC/ ACCAGACAAGAGTTTAAGAGATATGTATC  
SeV-Klf4 TTCCTGCATGCCAGAGGAGCCC/ AATGTATCGAAGGTGCTCAA  
SeV-cMyc TAACTGACTAGCAGGCTTGTCG/ TCCACATACAGTCCTGGATGATGATG  
SeV-KOS ATGCACCGCTACGAGTGAGCGC/ 
House-Keeping Genes (PCR) Hu18SRNA GTAACCCGTTGAACCCCATT/ CCATCCAATCGGTAGTAGCG  
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